Zuken Inc.
Price Action · 24 Months
From the ¥3,115 trough of August 5, 2024 the share climbed to ¥5,820 by July 17, 2025 — an 87% move on a sequence of disclosures that proved the operating-leverage mechanic, restated the capital-return framework, and laid out a three-year mid-term plan. Nine months later the share had given back about a quarter, even as the company printed its fifth consecutive year of record sales and operating profit. The open question is what the next four quarters resolve about the multiple, the dividend floor, and the model-based systems engineering leg.
01 · THE RALLY Zuken sells the design-automation software that turns an electrical engineer's schematic intent into the physical artifact of a working circuit board, the wire harness running through an automobile, or the systems-engineering model behind a defense or aerospace program — a fifty-year engineering franchise built around five product families and an installed base measured in decades of locked-in design libraries at Japanese OEMs and at the European industrial and rail-equipment manufacturers that adopted the E3.series wire-harness toolchain after Zuken's 2006 CIM-TEAM transaction. The flywheel runs in three layers: a license sale of CR-8000 or E3.series, an attached Client Services contract that renews annually for the life of the install, and a DS-series engineering-data-management layer that compounds with each new design vintage. Client Services has climbed to 42.9% of FY3/26 revenue, growing +9.1% against the license book's +3.5%, and order backlog at fiscal year-end reached ¥26.22bn (+25%) — roughly six months of forward revenue locked. The rally that took the share from ¥3,115 on August 5, 2024 to ¥5,820 on July 17, 2025 sat on three disclosures: the November 2024 introduction of a DOE-≥5% capital-return floor, the May 2025 FY3/25 print of operating profit up 12.4% against revenue up 5.9% that confirmed real operating leverage from segment mix toward Client Services and Japan, and the simultaneous announcement of a fresh ¥3bn buyback alongside a three-year mid-term plan targeting ¥49bn revenue and ¥7.4bn operating profit by FY3/28.
02 · THE REVERSAL On August 6, 2025 the Q1 FY3/26 tanshin disclosed sales ¥9,119M (+1.1%) and operating profit ¥827M (−3.4%) — an optical reversal that read as the front edge of a back-end-loaded year. The reasoning was visible in the same disclosure: the MTP had explicitly placed the heavier sales lift in years two and three, and the Q1 personnel cost increase reflected the ¥200M-per-year 3DIC research budget that management had built into the plan as a structural investment phase. From the July 17 peak of ¥5,820 the share compressed to ¥4,500 by late January 2026, a 23% retracement against a backdrop in which the company's actual operating disclosures kept ratifying the back-half acceleration: October 2025 saw Artisan Partners file an 8.11% large-holder report and become a significant foreign holder; November 2025 added a ¥100 commemorative dividend for the company's fiftieth anniversary, lifting FY3/26 total DPS to ¥200; December 2025's MTP-progress briefing reframed the strategic frame around three keywords — semiconductor, autonomous AI, and model-based systems engineering — and announced participation in the Resonac-led JOINT3 consortium for next-generation organic-panel substrate packaging. The market read the timing-of-cost mismatch as an MTP-execution question and held the price down even as the order backlog kept widening.
03 · WHERE WE STAND NOW The FY3/26 tanshin filed on May 14, 2026 closed the question on the back-half. Sales landed at ¥43,101M (+5.8%); operating profit reached ¥5,865M (+8.8%), beating the ¥5,600M guide by 4.7%; ordinary profit climbed to ¥7,134M (+20.2%) on a record ¥900M equity-method profit contribution from the Business Engineering Corp affiliate; group operating margin expanded forty basis points to 13.6%; and the FY3/27 guide called for the operating-profit growth rate to accelerate from +8.8% to +14.2% on revenue growth of +6.7%, with ordinary dividend per share raised to ¥150 — a 50% lift on the FY3/25 ordinary base of ¥100. The ¥3bn yen-cap buyback authorized in May 2025 completed in late January 2026 — the second consecutive year of near-full-envelope execution after FY3/25's ¥2.5bn programme — bringing the trailing-twelve-month total payout to 134% of net income and the treasury share count to 5.3% of the issued base. What the next four quarters resolve is whether the FY3/27 ¥6.7bn guide proves conservative against the MTP-end ¥7.4bn target, whether the eight-year Americas-segment operating loss closes during the plan as the GENESYS MBSE leg scales toward FY3/28's ¥3bn target, and whether the FY3/27 results introduce a deployment framework for the ¥36.1bn cash pile that the two-year buyback program has only just begun to absorb.
Live Investor Debates
Three open questions surface in the company's recent quarterly disclosures and in the FY3/26 results briefing Q&A. Each one settles a different part of the multiple.
Capital-Efficiency Levers
Three disclosure or capital-policy levers drawn from the company's blind spots in the TB Module 9 analysis. Each could reweight the multiple without requiring higher earnings.
Scenario Pathways
Three internally-consistent scenarios across the next four quarters. Each describes a different bundle of disclosure and operating outcomes — no single scenario is forecast; they are analytical bookends.
- Q3 FY3/27 (Feb 2027) prints group operating margin below 13% with revenue growth below +5% year-on-year.
- FY3/27 Americas segment operating loss exceeds ¥-400M; MTP mid-point MBSE revenue below ¥2.0bn.
- FY3/27 results retain DOE 5% as the floor; no incremental buyback authorization; cash crosses ¥38bn.
- B-EN-G equity-method profit normalizes from ¥900M back toward ¥500M; ordinary income growth turns negative.
- FY3/28 MTP guidance held but with explicit caveats on the back-end-loaded ¥7.4bn operating-profit target.
The bear band of ¥3,600–¥4,200 implies ~7–9x FY3/27 forward EV/EBIT — meaningfully below the Japanese listed software peer band of 11–14x and at parity with the JP private-buyer 7–10x cohort that Renesas paid for Altium in February 2024.
- FY3/27 prints sales ¥46.0bn ±2%, OP ¥6.7bn ±5%, NP ¥5.7bn ±5%.
- FY3/27 ordinary dividend ¥150 paid; one additional ~¥3bn buyback authorized at the FY3/27 results.
- Americas segment narrows the operating loss further to ¥-200M or breakeven; MBSE revenue tracks ¥2.5bn.
- Asia segment holds the 29% operating margin on ¥2.4bn of revenue; Europe stabilizes at 10% margin.
- At least one of (MBSE customer count, MTP-component revenue table, stepped DOE floor at 7%) materializes during FY3/27.
- FY3/27 operating profit exceeds the ¥6.7bn guide by 5% or more; group operating margin lands at or above 15%.
- Board authorizes a DOE 7% floor or an explicit recurring buyback above ¥3bn per year at the FY3/27 results.
- 3DIC program produces a disclosed customer win (Resonac JOINT3 conversion or IBM AI-chip packaging commercial license).
- Americas segment reaches operating breakeven during FY3/27; MBSE revenue at MTP mid-point lands at or above ¥2.7bn.
- FY3/28 MTP target ¥7.4bn looks achievable on FY3/27 trajectory — the back-end-loaded final step is set up by H1 FY3/28 visibility.
The bull band of ¥5,400–¥6,400 implies ~11–14x FY3/27 forward EV/EBIT — within the asset-light Japanese software peer band and meaningfully below the global EDA peer band of 17–22x at Cadence and Synopsys. The implied multiple at the upper bull band sits two turns above today's 9.8x.
This is not investment advice.
Japan Investor Interface Co., Ltd. ("JII") is an investor-relations (IR) consultancy. JII is not a registered investment advisor, financial advisor, broker-dealer, or securities firm in any jurisdiction. JII is not registered as a Financial Instruments Business Operator under Japan's Financial Instruments and Exchange Act. JII does not have an Investment Advisory and Agency Business registration and does not provide investment advice or solicit the purchase, sale, or holding of any security.
JII Compounders is an editorial publication. Each profile is an analytical study of how publicly disclosed information about a Japanese listed company has been received by the market. It is intended for educational and research purposes for IR professionals, finance students, journalists, and other readers interested in corporate disclosure practice. Nothing in this publication constitutes a recommendation, opinion, suggestion, or solicitation to buy, sell, or hold any security, derivative, or other financial instrument. Price targets, scenario ranges, multiples, and comparable-company references are illustrative of analytical method only and must not be interpreted as JII's investment opinion. JII does not have an investment opinion on any security discussed.
No reliance. The information presented may be incomplete, out of date, or incorrect. Forward-looking statements are inherently uncertain. Past price performance does not indicate future results. Estimates and scenario figures are not predictions and may not be achieved. JII makes no representation or warranty, express or implied, regarding the accuracy, completeness, timeliness, or reliability of any information in this publication.
No fiduciary or advisory relationship. Reading this publication does not create any advisory, fiduciary, or professional relationship between you and JII. Before making any investment, tax, accounting, legal, or other decision, you should consult qualified, licensed advisors in your jurisdiction and conduct your own independent due diligence based on primary disclosures issued by the company concerned.
Conflicts & positions. JII may provide paid IR diagnostic, translation, or interpretation services to Japanese listed companies, including companies discussed in this publication. JII does not trade in or hold positions in the securities of companies profiled. Where a JII engagement exists with a profiled company, that fact will be disclosed at the top of the profile.
Trademarks & data. Company names, logos, tickers, and product names referenced are the property of their respective owners. Share-price data is licensed from third-party providers. TradingView is a trademark of TradingView, Inc. All rights reserved.
本資料は、日本の金融商品取引法に基づく投資助言・代理業ではなく、特定の有価証券の売買その他の取引の勧誘・推奨を目的とするものではありません。本資料は教育・研究を目的とした分析記事であり、JII（株式会社ジャパン・インベスター・インターフェース）は、本資料の内容に基づく投資判断について一切の責任を負いません。投資の判断はご自身の責任と独立した調査に基づいて行ってください。